



truscreen
a world without
cervical cancer

NZX Announcement

15 December 2020

ASX APPROVES TRUSCREEN TO OFFICIAL LIST – OFFER TO CLOSE 18 DECEMBER 2020

TruScreen Group Limited (NZX: TRU) (TruScreen or the Company) is pleased to advise that ASX has confirmed it will admit TruScreen to the Official List of ASX subject to the satisfaction of certain conditions precedent outlined below. TruScreen confirms that it will be able to comply with all conditions following closure of the offer on 18 December 2020.

Conditions of Admission

- Closure of the offer under the Product Disclosure Statement ('PDS' or 'Prospectus') and completion of the issue of at least 14,285,714 ordinary fully paid shares at an issue price of NZ\$0.07.
- Confirmation that TruScreen has received cleared funds for the complete amount of the issue price of every fully paid security issued to every successful applicant for fully paid securities under the Prospectus
- Confirmation that TruScreen has been registered as a foreign company under the Corporations Act 2001 (Cth).

Conditions of quotation

- The issue of holding notices for shares issued, and refund money for those applicants unsuccessful
- Provision of the following documents for release to the market:
 - Appendix 1C, Information Form and Checklist and Annexure 2
 - PDS
 - TruScreen Constitution
 - Pro Forma statements of Financial Position
 - Updated pro forma statement of financial position based on the actual amount raised under the Prospectus
 - A distribution schedule of the numbers of holders in each class of security to be quoted, setting out the number and percentage holding as set out in Appendix 1A and Information Form and Checklist
 - A statement setting out the names of the 20 largest holders of each class of securities to be quoted, including the number and percentage for each class of securities held by those holders.

As outlined in the PDS lodged with the NZX on 11 November 2020, applications can be made through the online application portal at <https://www.truscreenshareoffer.co.nz/>. A copy of the registered PDS in support of the Offer is available on the online application portal. Australian applications can be made at www.onmarket.com.au

-ENDS-



For more information, visit www.truscreen.com or contact:

Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and NMPA (formerly CFDA) approved for sale in China. The global market potential for TruScreen is significant.